Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Leuk Lymphoma
    September 2025
  1. WANG Y, Xiao X, Zheng H, Bai J, et al
    The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Lymphoma. 2025 Sep 9:1-16. doi: 10.1080/10428194.2025.2549519.
    >> Share

  2. PARISI X, Ghosh A, Tang G, Jorgensen JL, et al
    Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy.
    Leuk Lymphoma. 2025 Sep 8:1-4. doi: 10.1080/10428194.2025.2549515.
    >> Share

  3. SINGH L, Rastogi K, Singh A, Sathapathy S, et al
    Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia-a systematic review.
    Leuk Lymphoma. 2025 Sep 5:1-13. doi: 10.1080/10428194.2025.2550580.
    >> Share

  4. XU K, Mellios Z, Hyun J, Childerhouse A, et al
    Diagnosis and management of acute erythroid leukemia (AEL).
    Leuk Lymphoma. 2025 Sep 2:1-5. doi: 10.1080/10428194.2025.2553166.
    >> Share

  5. BRAZEL D, Hermel DJ, Saven A
    Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.
    Leuk Lymphoma. 2025 Sep 1:1-8. doi: 10.1080/10428194.2025.2548373.
    >> Share

  6. ABBASI-SHAHKOUH A, Rashidan K, Azadmehr A, Atashi A, et al
    Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2547990.
    >> Share

    August 2025
  7. TESSIER S, Greipp PT, Jevremovic D, Alkhateeb HB, et al
    Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
    Leuk Lymphoma. 2025 Aug 25:1-6. doi: 10.1080/10428194.2025.2547988.
    >> Share

  8. LIPTON JH
    Indolent chronic myeloid leukemia - a historical dinosaur?
    Leuk Lymphoma. 2025 Aug 22:1-2. doi: 10.1080/10428194.2025.2536121.
    >> Share

  9. AMIRI D, Mirzaei M, Bahri T, Barkhordar M, et al
    Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
    Leuk Lymphoma. 2025 Aug 20:1-9. doi: 10.1080/10428194.2025.2548968.
    >> Share

  10. KARRAR O, Kantarjian H, Haddad FG, Azevedo RS, et al
    Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.
    Leuk Lymphoma. 2025 Aug 9:1-8. doi: 10.1080/10428194.2025.2542946.
    >> Share

  11. MATSUI S, Nakahara W, Fukuda S, Hosoya M, et al
    Intrathecal methotrexate for meningeal acute lymphoblastic leukemia in a hemodialysis patient.
    Leuk Lymphoma. 2025 Aug 9:1-4. doi: 10.1080/10428194.2025.2544067.
    >> Share

  12. PARK H, Lee JH, Lee JH, Park HS, et al
    Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Leuk Lymphoma. 2025 Aug 7:1-11. doi: 10.1080/10428194.2025.2541302.
    >> Share

  13. AGRAWAL V, Aldoss I, Pullarkat V
    Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
    Leuk Lymphoma. 2025 Aug 5:1-12. doi: 10.1080/10428194.2025.2541024.
    >> Share

  14. ZIELONKA K, Izdebski B, Drozd-Sokolowska J, Pruszczyk-Matusiak K, et al
    Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.
    Leuk Lymphoma. 2025 Aug 1:1-9. doi: 10.1080/10428194.2025.2535693.
    >> Share

    July 2025
  15. LU L, Liang J, Wang L, Chen Z, et al
    Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10.
    Leuk Lymphoma. 2025 Jul 31:1-11. doi: 10.1080/10428194.2025.2540445.
    >> Share

  16. PODGORICA M, Drivet E, Vestbostad J, Kvam AK, et al
    Azaindole 1, a selective Rock1/2 kinase inhibitor, induces G2/M arrest and cell death in B-cell acute lymphoblastic leukemia (B-ALL).
    Leuk Lymphoma. 2025 Jul 29:1-5. doi: 10.1080/10428194.2025.2536125.
    >> Share

  17. MULLIGAN SP, Thompson PA, Wight J, Anderson MA, et al
    Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.
    Leuk Lymphoma. 2025 Jul 27:1-11. doi: 10.1080/10428194.2025.2533498.
    >> Share

  18. LIU YC, van Besien KW
    Chronic myelomonocytic leukemia (CMML): a genetically heterogeneous entity.
    Leuk Lymphoma. 2025 Jul 22:1-3. doi: 10.1080/10428194.2025.2527389.
    >> Share

  19. WU Y, Ke Q, Liu B, Luo W, et al
    KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications.
    Leuk Lymphoma. 2025 Jul 15:1-5. doi: 10.1080/10428194.2025.2532680.
    >> Share

  20. LI THS, Yuen CT, Hou HW, Lam CP, et al
    Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation.
    Leuk Lymphoma. 2025 Jul 14:1-3. doi: 10.1080/10428194.2025.2529451.
    >> Share

  21. ASHFAQ MO, Iqbal MS, Ashfaq L, Irfan U, et al
    Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report.
    Leuk Lymphoma. 2025 Jul 13:1-4. doi: 10.1080/10428194.2025.2526792.
    >> Share

  22. KOFFMAN B, Warwick L, Haggert P, Patten PEM, et al
    A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence.
    Leuk Lymphoma. 2025 Jul 12:1-7. doi: 10.1080/10428194.2025.2521656.
    >> Share

  23. UYANIK MS, Jabbour E, Short N, Sasaki K, et al
    Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients.
    Leuk Lymphoma. 2025 Jul 6:1-3. doi: 10.1080/10428194.2025.2521649.
    >> Share

  24. FENG J, Qian W, Shan S, Wang G, et al
    Azathioprine as a substitute for 6-mercaptopurine in childhood acute lymphoblastic leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2025 Jul 6:1-9. doi: 10.1080/10428194.2025.2526795.
    >> Share

  25. GULLAKSEN SE, Omsland M, Brevik M, Letzner J, et al
    CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2025;66:1211-1220.
    >> Share

    June 2025
  26. SLATER VE, Carnahan RM, Strouse CS, O'Rorke MA, et al
    Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
    >> Share

  27. SARANGARAJAN S, Meena JP, Gupta AK, Batra A, et al
    The prognostic implications of CDKN2A/2B deletion in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2025 Jun 25:1-14. doi: 10.1080/10428194.2025.2521658.
    >> Share

  28. MAURO MJ, Hehlmann R, Williams LA, Goldberg SL, et al
    Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
    Leuk Lymphoma. 2025 Jun 22:1-10. doi: 10.1080/10428194.2025.2495369.
    >> Share

  29. SWAIN RN, Pattanaik S, Jain A, Wadhera S, et al
    Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough.
    Leuk Lymphoma. 2025 Jun 22:1-5. doi: 10.1080/10428194.2025.2519921.
    >> Share

  30. KUNDU R, Soni K, Kundu R, Mukherjee S, et al
    State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA).
    Leuk Lymphoma. 2025 Jun 20:1-6. doi: 10.1080/10428194.2025.2515598.
    >> Share

  31. PUROHIT BN, Mohan V, Capoor V, Jain S, et al
    Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia.
    Leuk Lymphoma. 2025 Jun 18:1-4. doi: 10.1080/10428194.2025.2519920.
    >> Share

  32. LAI CE, Leahy TP, Turner AJ, Thomassen A, et al
    Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control
    Leuk Lymphoma. 2025 Jun 13:1-12. doi: 10.1080/10428194.2025.2514894.
    >> Share

  33. SMITH CIE
    Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C.
    Leuk Lymphoma. 2025 Jun 12:1-2. doi: 10.1080/10428194.2025.2518433.
    >> Share

  34. DAMPMANN M, von Tresckow B, Reinhardt HC, Kuppers R, et al
    Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor.
    Leuk Lymphoma. 2025 Jun 10:1-10. doi: 10.1080/10428194.2025.2513005.
    >> Share

  35. KAMALLOO H, Fathi M, Bavandi S, Asadi F, et al
    Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jun 2:1-13. doi: 10.1080/10428194.2025.2507198.
    >> Share

  36. JANY J, Mikesch JH, Wethmar K, Baden D, et al
    Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
    Leuk Lymphoma. 2025 Jun 2:1-12. doi: 10.1080/10428194.2025.2512029.
    >> Share

    May 2025
  37. LEVY V, Srivastava T, Gautam R, Swami S, et al
    Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501.
    >> Share

  38. MEHTA P, Ngo D, Tinajero J, Agrawal V, et al
    Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
    Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003.
    >> Share

  39. SHI C, Li Y, Zou X, Yao D, et al
    AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161.
    >> Share

  40. HILL JW, Marvin-Peek J, Sasaki K, Bresser S, et al
    Central nervous system relapse of core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505.
    >> Share

  41. TADMOR T, Lavie G, Melamed G, Alapi H, et al
    Intake of benzodiazepines in treatment naive chronic lymphocytic leukemia patients is associate with a shorter time to first treatment.
    Leuk Lymphoma. 2025 May 15:1-6. doi: 10.1080/10428194.2025.2504155.
    >> Share

  42. OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al
    Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333.
    >> Share

  43. GORDON BK, Woyach JA
    The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics.
    Leuk Lymphoma. 2025;66:838-846.
    >> Share

  44. MCKEAGUE S, Tam C
    Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future.
    Leuk Lymphoma. 2025;66:847-857.
    >> Share

  45. RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al
    Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
    Leuk Lymphoma. 2025;66:920-929.
    >> Share

    April 2025
  46. SHALLIS RM, Weiss JJ, Winer ES, Badar T, et al
    Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Leuk Lymphoma. 2025 Apr 28:1-5. doi: 10.1080/10428194.2025.2496339.
    >> Share

  47. LAGANA A, Kasmi D, Diverio D, Bisegna ML, et al
    CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD(mut)-AML): a flow-cytometric marker for an accurate diagnostic workup.
    Leuk Lymphoma. 2025 Apr 28:1-6. doi: 10.1080/10428194.2025.2497392.
    >> Share

  48. ELHODAKY M, Duckett D, Santana-Santos L, Oh TS, et al
    Clinicopathological and global methylation profiling of acute myeloid leukemia with mutations in NPM1 and clonal hematopoiesis-related genes.
    Leuk Lymphoma. 2025 Apr 25:1-8. doi: 10.1080/10428194.2025.2495105.
    >> Share

  49. BEHMAN J, Longobardi S, Kang G, Lingamurthy M, et al
    CD5- B-cell lymphocytic leukemia -a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus.
    Leuk Lymphoma. 2025 Apr 22:1-4. doi: 10.1080/10428194.2025.2492608.
    >> Share

  50. LEVANON E, Peles I, Meyer E, Tarab E, et al
    Prognostic impact of fever at presentation in acute myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2025 Apr 17:1-11. doi: 10.1080/10428194.2025.2493342.
    >> Share

  51. PATEL M, Zabor EC, Mohamed A, Zureigat H, et al
    Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center.
    Leuk Lymphoma. 2025 Apr 9:1-6. doi: 10.1080/10428194.2025.2482131.
    >> Share

  52. DHAKAL P, Armitage JO, Bhatt VR
    Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.
    Leuk Lymphoma. 2025 Apr 1:1-11. doi: 10.1080/10428194.2025.2484640.
    >> Share

    March 2025
  53. KUGLER E, Dasdemir E, Bataller A, Wang B, et al
    Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.
    Leuk Lymphoma. 2025 Mar 31:1-13. doi: 10.1080/10428194.2025.2477723.
    >> Share

  54. JOHANSSON ALM S, Orrsjo G, Shah Barkhordar G, Rehammar A, et al
    Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.
    Leuk Lymphoma. 2025 Mar 31:1-11. doi: 10.1080/10428194.2025.2482130.
    >> Share

  55. FERREIRA JE, Wang CP, Aguayo-Hiraldo P, Raca G, et al
    Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy.
    Leuk Lymphoma. 2025 Mar 25:1-5. doi: 10.1080/10428194.2025.2482135.
    >> Share

  56. ROBAK T, Pluta A, Robak P, Janus A, et al
    Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
    Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
    >> Share

  57. JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al
    Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132.
    >> Share

  58. MONSEES EL, Hauch RT, Wrzeszcz A, Spohn M, et al
    A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation - implementation for the selection of MRD-targets.
    Leuk Lymphoma. 2025 Mar 19:1-5. doi: 10.1080/10428194.2025.2480395.
    >> Share

  59. AMREIN PC, Preffer FI, Fell G, Attar EC, et al
    Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
    Leuk Lymphoma. 2025 Mar 12:1-11. doi: 10.1080/10428194.2025.2476655.
    >> Share

  60. HOECHSTETTER MA, Wendtner CM
    Clinical trials in early-stage CLL: what has been learned and what's next?
    Leuk Lymphoma. 2025;66:378-388.
    >> Share

  61. ALHAJAHJEH A, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.
    Leuk Lymphoma. 2025;66:488-496.
    >> Share

  62. LI Q, Xing S, Zhang H, Mao X, et al
    FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.
    Leuk Lymphoma. 2025;66:507-515.
    >> Share

    February 2025
  63. TAN M, Lasica M, Donati V, Rady K, et al
    Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.
    Leuk Lymphoma. 2025 Feb 27:1-7. doi: 10.1080/10428194.2025.2470784.
    >> Share

  64. GRUESSNER C, Wiestner A, Sun C
    Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
    Leuk Lymphoma. 2025 Feb 19:1-13. doi: 10.1080/10428194.2025.2466101.
    >> Share

  65. SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al
    Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.
    Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341.
    >> Share

  66. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    >> Share

  67. THOMAS CJ, Porter D, Van Deerlin VM, Bhattacharyya S, et al
    Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-4. doi: 10.1080/10428194.2025.2462950.
    >> Share

  68. LANG F, Voss A, Kobbe G, Junghanss C, et al
    Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737.
    >> Share

  69. CHIN KK, Derkach A, Famulare C, Gupta GK, et al
    HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.
    Leuk Lymphoma. 2025;66:270-278.
    >> Share

    January 2025
  70. KRSTEVSKA BOZHINOVIKJ E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, et al
    Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 22:1-8. doi: 10.1080/10428194.2025.2456100.
    >> Share

  71. JEONG Y
    Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
    Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2453093.
    >> Share

  72. TESSIER S, McCullough KB, Gangat N, Begna KH, et al
    Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 16:1-5. doi: 10.1080/10428194.2024.2443017.
    >> Share

  73. HEILBRONNER AK, Blumberg O, Krez A, McMahon DJ, et al
    High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 15:1-4. doi: 10.1080/10428194.2025.2452340.
    >> Share

  74. ZHU H, Zhang C, Huang L, Zhang B, et al
    Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.
    Leuk Lymphoma. 2025 Jan 15:1-12. doi: 10.1080/10428194.2025.2451064.
    >> Share

  75. LI M, Zhao DQ, Kong XY, Wang SM, et al
    Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 11:1-11. doi: 10.1080/10428194.2025.2451059.
    >> Share

  76. SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al
    Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
    Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582.
    >> Share

  77. ZHANG F, Liu Y, Zhu Y, Wang Q, et al
    Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-11. doi: 10.1080/10428194.2024.2441855.
    >> Share

  78. YSEBAERT L, Mouchel PL, Laurent C, Quillet-Mary A, et al
    The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-13. doi: 10.1080/10428194.2024.2447362.
    >> Share

    December 2024
  79. AVGERINOU G, Solomou EE, Filippidou M, Perganti F, et al
    Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2445701.
    >> Share

  80. GUGLIELMANA V, Rossi D
    Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2441858.
    >> Share

  81. NILSSON MS, Martner A, Wennstrom L, Hansson M, et al
    Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Dec 24:1-3. doi: 10.1080/10428194.2024.2444466.
    >> Share

  82. DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al
    Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
    Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
    >> Share

  83. OLIAI C, Park S, Damon LE, Jonas BA, et al
    CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
    Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
    >> Share

  84. SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al
    The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
    Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
    >> Share

  85. ISHIKAWA C, Mori N
    ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.
    Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
    >> Share

  86. KOVACH AE, Komova D, Itov A, Gaskova M, et al
    Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
    Leuk Lymphoma. 2024;65:1840-1852.
    >> Share

  87. MINA A
    Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
    Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
    >> Share

  88. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    >> Share

  89. RIOS-OLAIS FA, Rodriguez-Rodriguez S, Mora-Canas A, Ramos-Penafiel CO, et al
    Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2432582.
    >> Share

  90. EHRMANN AS, Zadro A, Tausch E, Schneider C, et al
    The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.
    Leuk Lymphoma. 2024;65:1941-1953.
    >> Share

  91. ARAD-COHEN N, Messinger Y, Barzilai-Birenboim S, Ben-Harosh M, et al
    National study reveals gram negative bacteremia on contemporary pediatric AML protocol.
    Leuk Lymphoma. 2024;65:1991-1999.
    >> Share

  92. TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al
    The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.
    Leuk Lymphoma. 2024;65:2151-2162.
    >> Share

  93. BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al
    Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Leuk Lymphoma. 2024;65:2108-2115.
    >> Share

    November 2024
  94. PAUL S, Jabbour E, Nichols ED, Short NJ, et al
    Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.
    Leuk Lymphoma. 2024 Nov 29:1-11. doi: 10.1080/10428194.2024.2426052.
    >> Share

  95. SHORT NJ, Wierzbowska A, Cluzeau T, Laribi K, et al
    Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-11. doi: 10.1080/10428194.2024.2431878.
    >> Share

  96. MIMS A, Xie Z, Potluri R, Rotter D, et al
    Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792.
    >> Share

  97. COSTA A, Scalzulli E, Carmosino I, Ielo C, et al
    Clinical and biological advances of critical complications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 24:1-20. doi: 10.1080/10428194.2024.2425051.
    >> Share

  98. ARRIGO G, Scaldaferri M, Audisio E, Boscaro E, et al
    Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.
    Leuk Lymphoma. 2024 Nov 8:1-2. doi: 10.1080/10428194.2024.2427266.
    >> Share

  99. KORSHOLM C, Bulow C, Christensen M, Dalhoff K, et al
    Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Nov 7:1-11. doi: 10.1080/10428194.2024.2412289.
    >> Share

  100. LECORNEC N, Duchmann M, Itzykson R
    Single-cell sequencing applications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
    >> Share

  101. TAM C, Zhao FL, Azam S, Li SC, et al
    Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.
    Leuk Lymphoma. 2024;65:1576-1585.
    >> Share

    October 2024
  102. THARAKAN S, Tremblay D, Azzi J
    Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.
    Leuk Lymphoma. 2024 Oct 25:1-14. doi: 10.1080/10428194.2024.2414112.
    >> Share

  103. ROTTER LK, Alhajahjeh A, Stempel JM, Grimshaw AA, et al
    Analyzing determinants of premature trial discontinuation in leukemia clinical trials.
    Leuk Lymphoma. 2024 Oct 23:1-9. doi: 10.1080/10428194.2024.2416565.
    >> Share

  104. KIM SA, Jung M, Kim H, Byun JM, et al
    MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
    Leuk Lymphoma. 2024 Oct 22:1-8. doi: 10.1080/10428194.2024.2414903.
    >> Share

  105. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
    Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
    Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
    >> Share

  106. RIBERA JM, Torrent A
    Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Oct 18:1-11. doi: 10.1080/10428194.2024.2416569.
    >> Share

  107. KANKARIA RA, Jones JB, Zargari M, Alexander DW, et al
    Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.
    Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2416573.
    >> Share

  108. MOHAMMAD EM, El-Ayadi M, Kamel A, Ebeid E, et al
    Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.
    Leuk Lymphoma. 2024 Oct 9:1-7. doi: 10.1080/10428194.2024.2411432.
    >> Share

  109. SHANG Q, Wang Y, Lu A, Jia Y, et al
    Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
    Leuk Lymphoma. 2024 Oct 8:1-10. doi: 10.1080/10428194.2024.2406958.
    >> Share

  110. BRUNER SA, DiPippo AJ, Rausch CR
    Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center.
    Leuk Lymphoma. 2024 Oct 7:1-3. doi: 10.1080/10428194.2024.2411626.
    >> Share

  111. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
    Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
    >> Share

    September 2024
  112. ZABLONSKI KG, Skupa SA, Eiken AP, Sundaram S, et al
    Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 27:1-9. doi: 10.1080/10428194.2024.2398663.
    >> Share

  113. SHANGGUAN X, Huang Y, Chen C, Wu W, et al
    Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 23:1-12. doi: 10.1080/10428194.2024.2404957.
    >> Share

  114. KOPMAR NE, Qu X, Liu Y, Gooley TA, et al
    Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 19:1-4. doi: 10.1080/10428194.2024.2404959.
    >> Share

  115. DE SA H, Deloughery T, Kaempf A, Lachowiez C, et al
    Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 18:1-10. doi: 10.1080/10428194.2024.2405874.
    >> Share

  116. OMRAN MM, Ibrahim AB, Abdelfattah R, Moussa HS, et al
    The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib.
    Leuk Lymphoma. 2024 Sep 18:1-8. doi: 10.1080/10428194.2024.2403671.
    >> Share

  117. CHEN EC, Flamand Y, Tiao E, DeAngelo DJ, et al
    Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation.
    Leuk Lymphoma. 2024 Sep 16:1-8. doi: 10.1080/10428194.2024.2402808.
    >> Share

  118. YIN Z, Gao Y, Bu X, Wang J, et al
    Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
    Leuk Lymphoma. 2024 Sep 5:1-13. doi: 10.1080/10428194.2024.2400228.
    >> Share

  119. HUNTER S, Ryland G, Pang JM, Ninkovic S, et al
    Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.
    Leuk Lymphoma. 2024 Sep 4:1-4. doi: 10.1080/10428194.2024.2398659.
    >> Share

  120. GIL KB, Abbott D, Amaya ML, Schwartz M, et al
    Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 4:1-3. doi: 10.1080/10428194.2024.2397570.
    >> Share

  121. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
    Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
    >> Share

  122. HAYASHI H, Morikawa Y, Akahoshi S, Ikegawa K, et al
    Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study.
    Leuk Lymphoma. 2024;65:1366-1369.
    >> Share

  123. RAVANDI F, Subklewe M, Walter RB, Vachhani P, et al
    Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Leuk Lymphoma. 2024;65:1281-1291.
    >> Share

  124. ABUASAB T, Mohamed S, Pemmaraju N, Kadia TM, et al
    BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
    Leuk Lymphoma. 2024;65:1344-1349.
    >> Share

  125. SABILE JMG, Swords R, Tyner JW
    Evaluating targeted therapies in older patients with TP53-mutated AML.
    Leuk Lymphoma. 2024;65:1201-1218.
    >> Share

  126. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
    RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
    >> Share

    August 2024
  127. SCHWARTZ MS, Muffly LS
    Predicting relapse in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 31:1-7. doi: 10.1080/10428194.2024.2387728.
    >> Share

  128. OSTERGAARD A, Boer JM, van Leeuwen FN, Pieters R, et al
    IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
    Leuk Lymphoma. 2024 Aug 29:1-11. doi: 10.1080/10428194.2024.2396046.
    >> Share

  129. NGO D, Tinajero J, Song JY, Ma H, et al
    The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 18:1-9. doi: 10.1080/10428194.2024.2392823.
    >> Share

  130. PRASERTSAN P, McNeil EB, Songthawee N, Chavananon S, et al
    Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand.
    Leuk Lymphoma. 2024 Aug 18:1-7. doi: 10.1080/10428194.2024.2390582.
    >> Share

  131. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
    Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
    >> Share

  132. CELLINI A, Salvalaggio A, Velasco R, Arnan M, et al
    Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2391899.
    >> Share

  133. PELLAND AA, Deschenes-Simard X, Savard X, Giguere P, et al
    Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
    Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574.
    >> Share

  134. HU D, Shen K, Guo Y, Bao XB, et al
    The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study.
    Leuk Lymphoma. 2024 Aug 10:1-10. doi: 10.1080/10428194.2024.2387730.
    >> Share

  135. LIN L, Xue S, Chen J, Gu C, et al
    Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient.
    Leuk Lymphoma. 2024;65:1181-1185.
    >> Share

  136. VERVOORDELDONK MYL, Hengeveld PJ, Levin MD, Langerak AW, et al
    B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy.
    Leuk Lymphoma. 2024;65:1031-1043.
    >> Share

  137. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
    Leuk Lymphoma. 2024;65:1100-1109.
    >> Share

  138. CHARALAMPOUS C, Doucette K, Chappell A, Vesole DH, et al
    Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
    Leuk Lymphoma. 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.
    >> Share

    July 2024
  139. DALAL P, Dalal J
    PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
    >> Share

  140. CHOI YJ, Kook HW, Lee ST, Song J, et al
    The utility of next generation sequencing-based minimal residual disease monitoring in a post-myeloproliferative neoplasm acute myeloid leukemia patient: a case report.
    Leuk Lymphoma. 2024 Jul 29:1-4. doi: 10.1080/10428194.2024.2385498.
    >> Share

  141. JAIN U, Rahim F, Jain B, Tresa Mathew A, et al
    Trends in location of death for individuals with acute myeloid leukemia in the United States.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382330.
    >> Share

  142. ZHANG B, Mahsoub S, Weinberg O, Germans SK, et al
    Clinicopathologic characteristics of de novo NF1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382329.
    >> Share

  143. SRIPORNSAWAN P, Chavananon S, Kittivisuit S, Songthawee N, et al
    Long-term survival outcome of childhood acute myeloid leukemia: a 43-year experience in Thailand, a resource-limited country.
    Leuk Lymphoma. 2024 Jul 26:1-10. doi: 10.1080/10428194.2024.2382916.
    >> Share

  144. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
    Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
    Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
    >> Share

  145. FANG J, Shankar N, Bao L, Haag M, et al
    Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.
    Leuk Lymphoma. 2024 Jul 25:1-10. doi: 10.1080/10428194.2024.2382923.
    >> Share

  146. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
    Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
    Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
    >> Share

  147. MORENO-LORENZANA D, Juarez-Velazquez R, Reyes-Leon A, Martinez-Anaya D, et al
    CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.
    Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2378817.
    >> Share

  148. TRAN QUANG V, Wagner-Ballon O, Sloma I
    Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816.
    >> Share

  149. BORSOI L, Costa F, Milano C, Segantin G, et al
    Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.
    Leuk Lymphoma. 2024 Jul 9:1-11. doi: 10.1080/10428194.2024.2374041.
    >> Share

  150. HU M, Li J, Hu T, Zhang Z, et al
    Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
    >> Share

  151. DIEBOLD K, Bourne G, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-3. doi: 10.1080/10428194.2024.2373324.
    >> Share

  152. TORELI ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, et al
    Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
    Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057.
    >> Share

  153. LAVIE G, Tadmor T
    It's time to change the standard of care for hairy cell leukemia?!
    Leuk Lymphoma. 2024 Jul 5:1-3. doi: 10.1080/10428194.2024.2371497.
    >> Share

  154. ALHAJAHJEH A, Bewersdorf JP, Bystrom RP, Zeidan AM, et al
    Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
    Leuk Lymphoma. 2024 Jul 4:1-11. doi: 10.1080/10428194.2024.2367040.
    >> Share

  155. TAKIZAWA J, Teshima T, Ennishi D, Ichikawa S, et al
    Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
    Leuk Lymphoma. 2024 Jul 1:1-9. doi: 10.1080/10428194.2024.2370436.
    >> Share

  156. SURESH D, Rastogi P, Bal A, Lad D, et al
    Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.
    Leuk Lymphoma. 2024 Jul 1:1-16. doi: 10.1080/10428194.2024.2372408.
    >> Share

  157. GOERGEN E, Al-Sawaf O
    The prognostic significance of genomic complexity in patients with CLL.
    Leuk Lymphoma. 2024;65:873-881.
    >> Share

    June 2024
  158. ANDERSON LJ, Girguis M, Kim E, Shewale J, et al
    A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden.
    Leuk Lymphoma. 2024 Jun 27:1-10. doi: 10.1080/10428194.2024.2360536.
    >> Share

  159. YU G, Zhang W, Basyal M, Nishida Y, et al
    The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
    Leuk Lymphoma. 2024 Jun 13:1-16. doi: 10.1080/10428194.2024.2364839.
    >> Share

  160. ABE C, Keto J, Lilja M, Konradsen M, et al
    Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
    Leuk Lymphoma. 2024 Jun 11:1-9. doi: 10.1080/10428194.2024.2363430.
    >> Share

  161. BHATLA T, Cooper S, Hogan LE
    Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?
    Leuk Lymphoma. 2024 Jun 11:1-7. doi: 10.1080/10428194.2024.2362408.
    >> Share

  162. CHANG JE, Wang T, Kim K, Folstad M, et al
    Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
    >> Share

  163. SHORT NJ, Kantarjian H, Jabbour E
    Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
    Leuk Lymphoma. 2024 Jun 8:1-13. doi: 10.1080/10428194.2024.2364043.
    >> Share

  164. GERA K, Cline C, Al-Mansour Z, Medvec A, et al
    A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jun 6:1-9. doi: 10.1080/10428194.2024.2361111.
    >> Share

  165. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
    A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
    >> Share

  166. FREI CR, Ryan K, Obodozie-Ofoegbu GO, Moore AM, et al
    Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jun 4:1-4. doi: 10.1080/10428194.2024.2360526.
    >> Share

  167. FANG J, Bosma G, Aisner D, McMahon C, et al
    White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024;65:800-807.
    >> Share

    May 2024
  168. MINNEMA MC, Yin X, Davi R, Keeping S, et al
    Outcomes of patients aged >/=26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
    Leuk Lymphoma. 2024 May 24:1-10. doi: 10.1080/10428194.2024.2353877.
    >> Share

  169. BELDZINSKA-GADEK K, Zarzycka E, Pastuszak K, Borman K, et al
    Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
    Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2351194.
    >> Share

  170. ZHENG Y, Li J, Wen H, Weng K, et al
    Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020.
    Leuk Lymphoma. 2024 May 20:1-11. doi: 10.1080/10428194.2024.2350665.
    >> Share

  171. MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al
    Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700.
    >> Share

  172. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    >> Share

  173. WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al
    A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577.
    >> Share

  174. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
    Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
    Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
    >> Share

  175. ROGERS KA, Thompson PA
    Pairing obinutuzumab with venetoclax in relapsed CLL.
    Leuk Lymphoma. 2024;65:543-545.
    >> Share

  176. GARCIAZ S, Berton G, Hospital MA, Guille A, et al
    Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
    Leuk Lymphoma. 2024;65:700-703.
    >> Share

  177. OKABE S, Moriyama M, Gotoh A
    Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
    Leuk Lymphoma. 2024;65:696-699.
    >> Share

  178. FATIMA N, Shen Y, Crassini K, Burling O, et al
    The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
    Leuk Lymphoma. 2024;65:585-597.
    >> Share

    April 2024
  179. NESR G, Claudiani S, Milojkovic D, Innes A, et al
    Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
    >> Share

  180. STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
    Challenges in management of older patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
    >> Share

  181. BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
    >> Share

  182. FLECK C, Karabinos A, Cook A, Moore DC, et al
    Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
    >> Share

  183. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
    High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
    Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
    >> Share

  184. STEIN EM, Fathi AT, Harb WA, Colak G, et al
    Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
    Leuk Lymphoma. 2024;65:503-510.
    >> Share

  185. PARVIZ M, Agius R, Rotbain EC, Vainer N, et al
    Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning.
    Leuk Lymphoma. 2024;65:449-459.
    >> Share

  186. ALDOSS I, Clark MC, Wang X, Forman SJ, et al
    Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
    Leuk Lymphoma. 2024;65:440-448.
    >> Share

    March 2024
  187. CORTES J, Jonas BA, Schiller G, Mims A, et al
    Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
    Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
    >> Share

  188. MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
    Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
    Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
    >> Share

  189. ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
    Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
    >> Share

  190. LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
    RAD21 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
    >> Share

  191. ZHU J, Xu M, Ru Y, Gong H, et al
    Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
    >> Share

    February 2024
  192. NASKAR S, Paul T, Kulkarni JD, Anand KC, et al
    TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
    Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
    >> Share

  193. HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al
    Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey.
    Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171.
    >> Share

  194. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    >> Share

  195. TANG K, Lipton JH
    Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
    Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
    >> Share

  196. YARED JA, Lee TY, Cooke CE, Johnson A, et al
    Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
    Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
    >> Share

  197. EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
    The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
    Leuk Lymphoma. 2024;65:199-208.
    >> Share

  198. JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
    Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
    Leuk Lymphoma. 2024;65:209-218.
    >> Share

    January 2024
  199. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    >> Share

  200. NASR AA, Fund X, Barreau S, Desterke C, et al
    BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
    >> Share

  201. TADMOR T, Levy Yurkovski I
    Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
    Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
    >> Share

  202. FU S, Alhaj Z, Huynh D
    Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
    Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
    >> Share

  203. BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al
    Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
    Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738.
    >> Share

  204. NGO D, Tinajero J, Li S, Palmer J, et al
    Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
    Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473.
    >> Share

    December 2023
  205. SALTER B, Radford JM, Berg T, Leber B, et al
    The successful management of acute promyelocytic leukemia during pregnancy: a case report.
    Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786.
    >> Share

  206. MUTTI M, Cordella S, Parisotto A, Bettelli F, et al
    Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature.
    Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695.
    >> Share

  207. WANG L, Gao L, Liang Z, Cen X, et al
    Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study.
    Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465.
    >> Share

  208. JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al
    Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
    Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467.
    >> Share

  209. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
    Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
    Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
    >> Share

  210. MURTON A, Forsyth C, Ross DM, Grigg A, et al
    Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
    Leuk Lymphoma. 2023;64:2018-2025.
    >> Share

  211. STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al
    Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
    Leuk Lymphoma. 2023;64:1992-2001.
    >> Share

  212. REDD RA, Ford J, Lei M, Abramson JS, et al
    Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.
    Leuk Lymphoma. 2023;64:2296-2305.
    >> Share

  213. YANG T, Mahmood N, Goldberg B, Cevallos J, et al
    Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias.
    Leuk Lymphoma. 2023;64:2338-2342.
    >> Share

  214. TOMASULO E, Paul S, Mu R, Tian X, et al
    Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
    Leuk Lymphoma. 2023;64:2306-2315.
    >> Share

  215. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
    Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
    Leuk Lymphoma. 2023;64:2333-2337.
    >> Share

  216. ZHANG X, Wang T, Zhang Y, Wang F, et al
    Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
    Leuk Lymphoma. 2023;64:2133-2139.
    >> Share

    November 2023
  217. LAI X, Xiao J, Wang T, Hou C, et al
    Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
    Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
    >> Share

  218. OU J, Xu X, Deng S, Liang H, et al
    Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
    Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026.
    >> Share

  219. FATIMA N, Best OG, Belov L, Christopherson RI, et al
    The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
    Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530.
    >> Share

  220. KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al
    Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
    Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056.
    >> Share

  221. SASTOW D, Tatarian J, Salib C, Lin TL, et al
    Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658.
    >> Share

  222. FRATER JL
    Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749.
    >> Share

  223. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
    Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
    Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
    >> Share

  224. TRINQUAND A, Betts DR, Harte S, Sills A, et al
    Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061.
    >> Share

  225. RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al
    Role of IL8 in myeloid malignancies.
    Leuk Lymphoma. 2023;64:1742-1751.
    >> Share

  226. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
    RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
    >> Share

    October 2023
  227. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
    MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
    Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
    >> Share

  228. CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al
    SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752.
    >> Share

  229. HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al
    Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911.
    >> Share

  230. LIAO C, Nie J, Xu XJ, Zhang JY, et al
    The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075.
    >> Share

  231. ZAHID MF, Kainthla R
    Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene.
    Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428.
    >> Share

  232. GAUT D, Oliai C, Boiarsky J, Zhang S, et al
    Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
    >> Share

  233. YASU T, Gando Y, Shirota M, Kosugi N, et al
    Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
    Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427.
    >> Share

  234. SABILE JMG, Kaempf A, Tomic K, Manu GP, et al
    A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
    Leuk Lymphoma. 2023;64:1689-1694.
    >> Share

  235. CHAI J, Choudhuri J, Wang Q, Fang Y, et al
    Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Leuk Lymphoma. 2023;64:1662-1672.
    >> Share

    September 2023
  236. LI L, Zhang R, Cao W, Bian Z, et al
    Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
    >> Share

  237. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
    Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
    >> Share

  238. LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al
    Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
    Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123.
    >> Share

  239. IELO C, Scalzulli E, Carmosino I, Pepe S, et al
    Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
    Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804.
    >> Share

  240. LA J, Lee MH, Brophy MT, Do NV, et al
    Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434.
    >> Share

  241. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
    Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016